Glioblastoma (GBM) is the most commonly occurring of all malignant central nervous system (CNS) tumors in adults. Considering the low median survival of only ∼15 months and poor prognosis in GBM patients, despite surgical resection with adjuvant radiation and chemotherapy, it is vital to seek brand new and innovative treatment in combination with already existing methods. Hypothermia participates in many metabolic pathways, inflammatory responses, and apoptotic processes, while also promoting the integrity of neurons. Following the successful application of therapeutic hypothermia across a spectrum of disorders such as traumatic CNS injury, cardiac arrest, and epilepsy, several clinical trials have set to evaluate the potency of hypothermia in treating a variety of cancers, including breast and ovaries cancer. In regard to primary neoplasms and more specifically, GBM, hypothermia has recently shown promising results as an auxiliary treatment, reinforcing chemotherapy's efficacy. In this review, we discuss the recent advances in utilizing hypothermia as treatment for GBM and other cancers.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/ther.2023.0014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risperidone-Induced Hypothermia in a Cerebral Palsy Patient: A Case Report and Literature Review.
Cureus
December 2024
Internal Medicine, King Abdulaziz Specialist Hospital, Taif, SAU.
Cerebral palsy (CP) is a debilitating disorder that can lead to life-long disability, with a high incidence in Saudi Arabia. Secondary epilepsy and cardiac complications are common in CP patients. We present a rare case of a 17-year-old female with CP, attention-deficit hyperactivity disorder (ADHD), secondary epilepsy, and a history of post-cardiac arrest, with home medications carbamazepine, risperidone, and sodium valproate.
View Article and Find Full Text PDFComparison of Temporal Artery and Rectal Temperature Measurement During Cooling and Rewarming in Neonates Treated for Hypoxic Ischemic Encephalopathy.
Adv Neonatal Care
January 2025
Author Affiliations: Neonatal Intensive Care Unit, Seattle Children's Hospital, Seattle, WA (Mrs LaBella, Ms Kelly, Mrs Carlin, and Dr Walsh); and Seattle Children's Research Institute, Seattle, WA (Mrs Carlin and Dr Walsh).
Background: Finding an accurate and simple method of thermometry in the neonatal intensive care unit is important. The temporal artery thermometer (TAT) has been recommended for all ages by the manufacturer; however, there is insufficient evidence for the use of TAT in infants, especially to detect hypothermia.
Purpose: To assess the accuracy of the TAT in hypothermic neonates in comparison to a rectal thermometer.
Cardiovascular Performance in Neonates with Hypoxic-Ischemic Encephalopathy Under Therapeutic Hypothermia: Evaluation by Conventional and Advanced Echocardiographic Techniques.
Pediatr Cardiol
January 2025
Echocardiography Laboratory, Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil.
This study aimed to evaluate the hemodynamic and ventricular performance of neonates with hypoxic-ischemic encephalopathy (HIE) undergoing therapeutic hypothermia using conventional and advanced echocardiographic techniques. This observational, prospective study included 22 neonates with HIE matched with 22 healthy neonates. Echocardiographic studies were performed 24 h after achieving target temperature during hypothermia and 24 h after rewarming.
View Article and Find Full Text PDFSex Differences in Neurological Outcome at 6 and 12 Months Following Severe Traumatic Brain Injury. An Observational Analysis of the OXY-TC Trial.
J Neurotrauma
January 2025
Department of Anaesthesia and Intensive Care, Centre Hospitalier Universitaire Grenoble, and Inserm, U1216, Grenoble Institut Neurosciences, University Grenoble Alpes, Grenoble, France.
The effect of sex in outcomes after severe traumatic brain injury (TBI) remains uncertain. We explored whether outcomes differed between women and men after standardized care management during the first 5 days in the intensive care unit (ICU). This study was an observational analysis of the OXY-TC multicenter randomized clinical trial between June 15, 2016 and April 17, 2021.
View Article and Find Full Text PDFMethionine Sulfoximine as a Tool for Studying Temporal Lobe Epilepsy: Initiator, Developer, Attenuator.
Neurochem Res
January 2025
Department of Pathophysiology, Medical University of Lublin, 20-090, Lublin, Poland.
Methionine sulfoximine (MSO) is a compound originally discovered as a byproduct of agene-based milled flour maturation. MSO irreversibly inhibits the astrocytic enzyme glutamine synthase (GS) but also interferes with the transport of glutamine (Gln) and of glutamate (Glu), and γ-aminobutyric acid (GABA) synthesized within the Glu/Gln-GABA cycle, in this way dysregulating neurotransmission balance in favor of excitation. No wonder that intraperitoneal administration of MSO has long been known to induce behavioral and/or electrographic seizures.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!